revenues increasing, but ebitda isnt budging materially. valuation on traditional short run metrics its way over valued. near half a billion fully diluted. so being held by cannabis hype right now.
long run metrics is anything guesswork. who knows the competitive landscape. theres no IP here. its not biotech.
CWEB and CVSI have materially more earnings ebitda, and CWEB is the leader.
Ann: FY 2018 Investor Results Presentation, page-17
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EXL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.605M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $1.605K | 321.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 6265944 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 14532474 | 10 |
View Market Depth
| Last trade - 15.57pm 25/11/2024 (20 minute delay) ? |
| EXL (ASX) Chart |
